AU2006270162B2 - A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis - Google Patents
A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis Download PDFInfo
- Publication number
- AU2006270162B2 AU2006270162B2 AU2006270162A AU2006270162A AU2006270162B2 AU 2006270162 B2 AU2006270162 B2 AU 2006270162B2 AU 2006270162 A AU2006270162 A AU 2006270162A AU 2006270162 A AU2006270162 A AU 2006270162A AU 2006270162 B2 AU2006270162 B2 AU 2006270162B2
- Authority
- AU
- Australia
- Prior art keywords
- citrate
- calcium
- meq
- potassium
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 206010029148 Nephrolithiasis Diseases 0.000 title claims abstract description 29
- 208000000913 Kidney Calculi Diseases 0.000 title claims abstract description 28
- 239000000843 powder Substances 0.000 title claims abstract description 28
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 title abstract description 41
- SPGDAODMONVAAC-UHFFFAOYSA-K calcium;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SPGDAODMONVAAC-UHFFFAOYSA-K 0.000 title description 23
- 239000011575 calcium Substances 0.000 claims abstract description 84
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 80
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 79
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims abstract description 61
- 239000001508 potassium citrate Substances 0.000 claims abstract description 58
- 229960002635 potassium citrate Drugs 0.000 claims abstract description 58
- 235000011082 potassium citrates Nutrition 0.000 claims abstract description 58
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims abstract description 53
- 239000001354 calcium citrate Substances 0.000 claims abstract description 51
- 235000013337 tricalcium citrate Nutrition 0.000 claims abstract description 51
- 239000011591 potassium Substances 0.000 claims abstract description 36
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 36
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229960003975 potassium Drugs 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 93
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 50
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 48
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000000741 diarrhetic effect Effects 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 239000008122 artificial sweetener Substances 0.000 claims description 3
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 8
- 229940069978 calcium supplement Drugs 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 229940070017 potassium supplement Drugs 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 description 52
- 239000004575 stone Substances 0.000 description 26
- 239000003513 alkali Substances 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 206010065687 Bone loss Diseases 0.000 description 16
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 14
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 13
- 230000037213 diet Effects 0.000 description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 102000003982 Parathyroid hormone Human genes 0.000 description 6
- 108090000445 Parathyroid hormone Proteins 0.000 description 6
- 239000000199 parathyroid hormone Substances 0.000 description 6
- 229960001319 parathyroid hormone Drugs 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 235000012976 tarts Nutrition 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940070370 citracal Drugs 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000013110 gastrectomy Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 229940054512 urocit-k Drugs 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical group OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010044038 Tooth erosion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- -1 potassium cations Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/183,140 US20070077314A1 (en) | 2005-07-15 | 2005-07-15 | Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
| US11/183,140 | 2005-07-15 | ||
| PCT/US2006/027398 WO2007011740A2 (en) | 2005-07-15 | 2006-07-13 | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006270162A1 AU2006270162A1 (en) | 2007-01-25 |
| AU2006270162B2 true AU2006270162B2 (en) | 2012-01-12 |
Family
ID=37669400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006270162A Ceased AU2006270162B2 (en) | 2005-07-15 | 2006-07-13 | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20070077314A1 (enExample) |
| EP (1) | EP1922064A4 (enExample) |
| JP (1) | JP2009514786A (enExample) |
| AU (1) | AU2006270162B2 (enExample) |
| WO (1) | WO2007011740A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9278112B2 (en) * | 2013-03-15 | 2016-03-08 | New York University | Citrate containing beverage |
| US9529465B2 (en) * | 2013-12-02 | 2016-12-27 | At&T Intellectual Property I, L.P. | Secure interaction with input devices |
| US20150216825A1 (en) * | 2014-02-06 | 2015-08-06 | University Of Houston System | Organic acids as growth inhibitors of pathological calcification and uses thereof |
| US10285961B2 (en) | 2014-02-06 | 2019-05-14 | University Of Houston System | Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof |
| CN104069125B (zh) * | 2014-07-16 | 2017-02-08 | 华南理工大学 | 一种用于泌尿系磷酸盐结石的溶石剂及其制备方法 |
| WO2016159897A1 (en) * | 2015-04-01 | 2016-10-06 | Ay Doğan | Potassium citrate suspension |
| WO2019035989A1 (en) * | 2017-08-17 | 2019-02-21 | The Board Of Regents Of The University Of Texas System | PREVENTION OF CALCIUM OXALATE RENAL CALCULATIONS BY POTASSIUM HYDROXYCITRATE |
| IT202200021258A1 (it) * | 2022-10-14 | 2024-04-14 | Neilos S R L | “Composizione nutraceutica o farmaceutica per il benessere renale” |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001005250A1 (en) * | 1999-07-19 | 2001-01-25 | Mission Pharmacal Company | Potassium calcium citrate compositions and methods for production |
| US20020102331A1 (en) * | 2000-10-16 | 2002-08-01 | Chang Pei K. | Calcium-supplemented beverages and method of making same |
| US6599544B2 (en) * | 2000-01-26 | 2003-07-29 | American Micronutrients, Inc. | Calcium enrichment composition and method for producing the same |
| US20040009280A1 (en) * | 2002-07-08 | 2004-01-15 | Valencia Donna L. | Powdered beverage mix with rapidly dissolving calcium |
| US20040101597A1 (en) * | 2002-11-22 | 2004-05-27 | Calapini Sarah A. | Calcium fortified acidic beverages |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888182A (en) * | 1983-04-11 | 1989-12-19 | Board Of Regents Of The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4772467A (en) * | 1985-02-19 | 1988-09-20 | Board Of Regents, U T Systems | Osteoporosis inhibition by dietary calcium supplementation |
| US4722847A (en) * | 1986-05-07 | 1988-02-02 | The Procter & Gamble Company | Fruit juice beverages and juice concentrates nutritionally supplemented with calcium |
| US4871554A (en) * | 1987-08-12 | 1989-10-03 | Coca-Cola Company | Calcium fortified food product |
| US5128374A (en) * | 1987-08-28 | 1992-07-07 | The Procter & Gamble Company | Use of calcium citrate malate for the treatment of osteoporosis and related disorders |
| ES2061394B1 (es) * | 1993-02-05 | 1995-06-16 | Robert S A Lab | Procedimiento de fabricacion de un granulado de citrato potasico con cesion retardada. |
| US6680305B1 (en) * | 1993-06-04 | 2004-01-20 | Biotime, Inc. | Physiologically acceptable aqueous solutions and methods for their use |
| DE19503190A1 (de) * | 1995-02-01 | 1996-08-08 | Dietl Hans | Mittel zur Beeinflussung von Störungen der Knochenbildung |
| GB9603518D0 (en) * | 1996-02-20 | 1996-04-17 | Smithkline Beecham Plc | Novel process |
| US20030175360A1 (en) * | 2002-02-22 | 2003-09-18 | Renzo Luzzatti | Symptomatic relief of gastrointestinal disorders |
| US7507421B2 (en) * | 2002-04-30 | 2009-03-24 | Unibar Corporation | Hydroxycitric acid salt composition and method of making |
| US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
-
2005
- 2005-07-15 US US11/183,140 patent/US20070077314A1/en not_active Abandoned
-
2006
- 2006-07-13 AU AU2006270162A patent/AU2006270162B2/en not_active Ceased
- 2006-07-13 JP JP2008521643A patent/JP2009514786A/ja active Pending
- 2006-07-13 WO PCT/US2006/027398 patent/WO2007011740A2/en not_active Ceased
- 2006-07-13 EP EP06787322A patent/EP1922064A4/en not_active Withdrawn
-
2010
- 2010-05-20 US US12/784,305 patent/US8216614B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001005250A1 (en) * | 1999-07-19 | 2001-01-25 | Mission Pharmacal Company | Potassium calcium citrate compositions and methods for production |
| US6599544B2 (en) * | 2000-01-26 | 2003-07-29 | American Micronutrients, Inc. | Calcium enrichment composition and method for producing the same |
| US20020102331A1 (en) * | 2000-10-16 | 2002-08-01 | Chang Pei K. | Calcium-supplemented beverages and method of making same |
| US7052725B2 (en) * | 2000-10-16 | 2006-05-30 | Pepsico, Inc. | Calcium-supplemented beverages and method of making same |
| US20040009280A1 (en) * | 2002-07-08 | 2004-01-15 | Valencia Donna L. | Powdered beverage mix with rapidly dissolving calcium |
| US20040101597A1 (en) * | 2002-11-22 | 2004-05-27 | Calapini Sarah A. | Calcium fortified acidic beverages |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070077314A1 (en) | 2007-04-05 |
| AU2006270162A1 (en) | 2007-01-25 |
| JP2009514786A (ja) | 2009-04-09 |
| EP1922064A4 (en) | 2010-12-22 |
| WO2007011740A2 (en) | 2007-01-25 |
| US20100227006A1 (en) | 2010-09-09 |
| US8216614B2 (en) | 2012-07-10 |
| WO2007011740A3 (en) | 2009-04-30 |
| EP1922064A2 (en) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8216614B2 (en) | Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis | |
| AU2008216234B2 (en) | Improved stability in vitamin and mineral supplements | |
| DK169231B1 (da) | Calciumkosttilskudspræparat til opløsning i vand, fremgangsmåde til fremstilling af et sådant, fremgangsmåde til fremstilling af en drikkelig væske baseret derpå, og drikkelig væske, der er egnet som kosttilskud af calcium | |
| US8759398B2 (en) | Phosphorus binder composition for treatment of hyperphosphatemia | |
| CA2587924C (en) | Oral compositions for absorption of phosphorus compounds | |
| KR20110128329A (ko) | 인산염 흡착제 | |
| NO342559B1 (no) | Farmasøytisk formulering omfattende lantankarbonat og anvendelse av denne | |
| US8129430B2 (en) | Method of reducing phosphate nephropathy in a mammal | |
| US20130189377A1 (en) | Compositions | |
| CA2376017C (en) | Potassium calcium citrate compositions and methods for production | |
| JPS62501846A (ja) | 液体食事カルシウム補足 | |
| WO2007108712A1 (en) | Kit and method for treating or preventing anemia caused by iron deficiency | |
| WO2019201707A1 (de) | Stoffgemisch umfassend k-mg-citrat zur verwendung als arzneimittel | |
| RU2527042C1 (ru) | Биологически активная добавка к пище для профилактики заболеваний остеопорозом | |
| AU2018327614B2 (en) | Composition for calcium supplementation | |
| RU2835420C1 (ru) | Композиция для профилактики и лечения дефицита кальция и остеопороза | |
| RU2796676C1 (ru) | Водорастворимые таблетки колекальциферола и способ их получения | |
| CN102232964B (zh) | 治疗泌尿系统结石及高尿酸血症的药物组合物 | |
| US12251400B2 (en) | Liquid concentrates of calcium and magnesium | |
| US20110269837A1 (en) | Phosphorus binder composition for treatment of hyperphosphatemia | |
| US20200078395A1 (en) | Averting complications of pump inhibitor therapy by effervescent calcium magnesium citrate | |
| Abrahams et al. | Urinary Stone Inhibitors: Citrate and Magnesium | |
| SHLAFER et al. | 27 Drug therapy and nutrition | |
| JPH08508503A (ja) | 骨粗しょう症の治療のための方法及び組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY Free format text: FORMER APPLICANT(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; MISSION PHARMACAL CO. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |